Zankel Todd 4
4 · Raptor Pharmaceutical Corp · Filed May 2, 2012
Insider Transaction Report
Form 4
Zankel Todd
Chief Scientific Officer
Transactions
- Sale
Common Stock
2012-05-01$5.82/sh−3,929$22,867→ 686,834 total - Exercise/Conversion
Common Stock
2012-05-01$2.83/sh+3,643$10,310→ 690,477 total - Exercise/Conversion
Stock options (right to buy)
2012-05-01+3,643→ 313,136 totalExercise: $2.83From: 2006-11-25Exp: 2016-05-25→ Common Stock (3,643 underlying) - Sale
Common Stock
2012-05-01$5.84/sh−17,484$102,194→ 669,350 total - Exercise/Conversion
Stock options (right to buy)
2012-05-01+286→ 312,850 totalExercise: $2.02From: 2010-03-09Exp: 2020-03-08→ Common Stock (286 underlying) - Exercise/Conversion
Common Stock
2012-05-01$2.02/sh+286$578→ 690,763 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan executed on January 9, 2012.
- [F2]Original option grant vests 6/36ths on November 25, 2006 and 1/36th per month thereafter.
- [F3]Original option grant vests 6/48ths on March 9, 2010 and 1/48th per month thereafter.
- [F4]This transaction was executed in multiple trades at prices ranging from $5.77 to $5.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.